Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

Benzinga

Regeneron Pharmaceuticals announced it won the bankruptcy auction for key assets of 23andMe, according to Benzinga. The $256 million deal aims to expand its genetics-driven drug discovery efforts and is expected to close in the third quarter. The acquisition includes 23andMe’s Personal Genome Service, Total Health, Research Services, Biobank, and infrastructure, with Regeneron pledging no disruption to consumer services. Regeneron committed to maintaining 23andMe’s existing privacy protections, with oversight from a court-appointed Customer Privacy Ombudsman. Co-founder and chief scientific officer George D. Yancopoulos highlighted Regeneron’s commitment to DNA-based drug development.

Transcript

00:00It's Benzinga bringing Wall Street to Main Street.

00:02Regeneron Pharmaceuticals announced it won the bankruptcy auction for key assets of 23andMe,

00:07according to Benzinga.

00:09$256 million deals aimed at expanding its genetics-driven drug discovery efforts

00:13and is expected to close in the third quarter.

00:16The acquisition includes 23andMe's personal genome service,

00:19total health, research services, biobank, and infrastructure,

00:23with Regeneron pledging no disruption to consumer services.

00:26Regeneron committed to maintaining 23andMe's existing privacy protections

00:30with oversight from a court-appointed Custard Privacy Ombudsman.

00:34Co-founder and Chief Scientific Officer George G. Yakopoulos

00:38highlighted Regeneron's commitment to DNA-based drug development.

00:41For all things money, visit Benzinga.com slash GSTV.

Category

Transcript

Comments

Recommended